Lincoln Park Capital has provided Provectus Pharmaceuticals (OTCBB: PVCT) with $1 million of growth capital. The firm purchased 1 million shares of Provectus common stock for $1 apiece, which represented a 9.8% premium, and also received warrants to purchase 500,000 shares of common stock. LPC may invest up to an additional $30 million. The timing and amount of any related future investments will be determined by the company. Provectus is a development-stage oncology and dermatology biopharmaceutical company.